Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 801–900 of 1,012
Tanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 32
Yang, D.-Y. D., He, X., Liang, H., Zhang, S., Zhong, X., Luo, C., Du, Z., He, J., Zhuang, X., & Liao, X. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0853-x · Cited by 35
Diabetes Mellitus in Acute Coronary Syndrome
Stampouloglou, P. K., Anastasiou, A., Bletsa, E., Lygkoni, S., Chouzouri, F., Xenou, M., Κατσαρού, Ο., Theofilis, P., Zisimos, K., Tousoulis, D., et al. (2023) · Life · doi:10.3390/life13112226 · Cited by 40
“…of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, in subjects with DM and a recent ACS within 15 to 90 days before recruitment, proved the safety of DPP-4 inhibitors compared to placebo, with no increase in the rates of major adverse cardiovascular events [83].”
BackgroundMałyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
Jorsal, A., Wiggers, H., Holmager, P., Nilsson, B., Nielsen, R., Boesgaard, T. W., Kumme, A., Møller, J. E., Videbæk, L., Kistorp, C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004885 · Cited by 31
“EXAMINE and SAVOR-TIMI 53 which tested the DPP-4 inhibitors, alogliptin and saxagliptin, did not increase or decrease the rate of ischaemic events although the rate of hospitalisation for heart failure was slightly increased in SAVOR-TIMI 53.(24) 25 However, only a minority of patients had a heart failure diagnosis an…”
Sato, A., Yoshihisa, A., Kanno, Y., Takiguchi, M., Miura, S., Shimizu, T., Nakamura, Y., Yamauchi, H., Owada, T., Sato, T., et al. (2015) · ESC Heart Failure · doi:10.1002/ehf2.12079 · Cited by 30
“5 year follow-up, alogliptin did not increase or decrease the rate of major adverse cardiovascular events.(16) Table 2 Cox proportional hazard models of cardiac death and all-cause mortality in pre-matched cohort and post-matched cohort”
BackgroundAntihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus
Sharma, A., Cooper, L. B., Fiuzat, M., Mentz, R. J., Ferreira, J. P., Butler, J., FITCHETT, D. H., Moses, A. C., O’Connor, C. J., & Zannad, F. M. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.020 · Cited by 30
Self-citationCardiovascular outcome trials of the newer anti-diabetic medications
Acharya, T., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.003 · Cited by 31
Pleiotropic effects of anti-diabetic drugs: A comprehensive review
Nath, M., Bhattacharjee, K., & Choudhury, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173349 · Cited by 34
Yang, W., Cai, X., Zhang, S., Han, X., & Ji, L. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3391 · Cited by 32
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
Chen, L., Ma, S., Hu, D., Lin, H., Zhu, Y., Chen, K., Chen, L., Zheng, C., Liu, J., & Liao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561494 · Cited by 29
Jacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 34
“While cardiovascular safety in terms of MACE was confirmed [48], a signal for an excess of hospitalizations for heart failure was observed with saxagliptin [49] and, to a lesser extent, alogliptin [50].”
BackgroundPleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
Kang, S. M., & Park, J. H. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211051698 · Cited by 37
“BNP is synthesized as a 134-amino acid precursor protein (preproBNP) that is subsequently processed into proBNP, active BNP (1-32), and NT-proBNP (1-76).49 All of these forms have a proline in the second N-terminal position; therefore, they can be DPP-4 substrates.”
BackgroundTherapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
Hu, X., Wang, X., & Xue, X. (2022) · Molecules · doi:10.3390/molecules27144498 · Cited by 30
Abe, M., & Okada, K. (2015) · Contributions to nephrology · doi:10.1159/000380974 · Cited by 31
Do incretins improve endothelial function?
Oyama, J., Higashi, Y., & Node, K. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-21 · Cited by 37
Lim, S. K., Han, K. A., Yu, J., Chamnan, P., Kim, E. S., Yoon, K., Kwon, S. H., Moon, M. K., Lee, K. W., Kim, D., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12787 · Cited by 31
“Thus, the risk of pancreatitis because of gemigliptin administration was not elevated, which is consistent with recent studies of other DPP-IV inhibitors.(34,35) In addition, no clinically significant changes were observed in vital signs or ECG findings.”
ResultXu, S., Zhang, X., Tang, L., Zhang, F., & Tong, N. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1255537 · Cited by 32
Complications of Diabetes Mellitus
Brownlee, M., Aiello, L. P., Cooper, M. E., Vinik, A. I., Plutzky, J., & Boulton, A. J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00033-2 · Cited by 44
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease
Khan, H. M., Anker, S. D., Januzzi, J. L., McGuire, D. K., Sattar, N. A., Woerle, H. J., & Butler, J. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.10.015 · Cited by 33
Bertoluci, M. C., Salles, J. E. N., Silva‐Nunes, J., Pedrosa, H. C., Moreira, R. O., Duarte, R., Carvalho, D. M., Trujilho, F. R., Raposo, J. F. C. D. S., Parente, E. B., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00551-1 · Cited by 33
Taylor, O. M., & Lam, C. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100596 · Cited by 37
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 37
Boussageon, R., Gueyffier, F., & Cornu, C. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.12.010 · Cited by 30
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Górriz, J. L., Nieto, J., Navarro‐González, J. F., Molina, P., Martínez‐Castelao, A., & Pallardó, L. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4101866 · Cited by 34
“Two such trials for DPP-4 inhibitors have been published [69,72].”
Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction
Apaijai, N., Inthachai, T., Lekawanvijit, S., Chattipakorn, S. C., & Chattipakorn, N. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0096 · Cited by 28
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 30
Toh, S., Reichman, M. E., Graham, D. J., Hampp, C., Zhang, R., Butler, M. G., Iyer, A., Rucker, M., Pimentel, M., Hamilton, J., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0476 · Cited by 28
“16) for the primary end pointda composite of death from cardiovascular causes, nonfatal AMI, or nonfatal strokedwhen alogliptin was compared with placebo (31).”
BackgroundTrends in Diabetes Treatment and Monitoring among Medicare Beneficiaries
Landon, B. E., Zaslavsky, A. M., Souza, J., & Ayanian, J. Z. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4310-4 · Cited by 32
Cosenso‐Martin, L. N., Giollo-Júnior, L. T., Fernandes, L. A. B., Cesarino, C. B., Nakazone, M. A., Machado, M. D. N., Yugar‐Toledo, J. C., & Vilela-Martin, J. F. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1204-1 · Cited by 29
Saisho, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1776262 · Cited by 28
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 31
Reifsnider, O. S., Kansal, A. R., Gandhi, P., Cragin, L. S., Brand, S. B., Pfarr, E., Fahrbach, K. R., & Ustyugova, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001313 · Cited by 29
Evans, M., Kuodi, P., Akunna, C. J., McCreedy, N., Donsmark, M., Ren, H., & Nnaji, C. A. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641231221740 · Cited by 33
Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension
Liu, L., Liu, J., & Huang, Y. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000176 · Cited by 32
“Although some GLP-1–based therapies have cardiovascular benefits, the patients with type 2 diabetes were at higher risk for cardiovascular events after treatment with DPP-4 inhibitor saxagliptin(116) or alogliptin.(117) Furthermore, the effects of DPP-4 inhibitors on arterial blood pressure depend on types of inhibito…”
Background“Mild dysglycemia” in type 2 diabetes: to be neglected or not?
Monnier, L., Colette, C., Dejager, S., & Owens, D. R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.004 · Cited by 31
“Firstly, in the SAVOR-TIMI 53 (Scirica et al., 2013a) and the EXAMINE (White et al., 2013) studies the duration of follow-up could possibly be too short at only two years and the intervention probably implemented at too late advanced stage in the course of the disease.”
BackgroundMethodResultInfluentialSassoon, D., Goodwill, A. G., Noblet, J. N., Conteh, A. M., Herring, B. P., McClintick, J. N., Tune, J. D., & Mather, K. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-016-0563-4 · Cited by 28
“In contrast, large clinical trials of GLP-1 based therapies in humans with obesity and type 2 diabetes have failed to show the expected cardiovascular benefits to date [64, 70].”
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 32
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
Sato, S., Saisho, Y., Kou, K., Meguro, S., Tanaka, M., Irie, J., Kawai, T., & Itoh, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121988 · Cited by 29
“In addition, in this study, sitagliptin treatment showed some reduction in oxidative stress markers, which may also be favorable to prevent the development or progression of vascular complications, although a favorable effect of DPP-4 inhibitors on cardiovascular outcome remains to be established[26, 27].”
BackgroundAntihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 30
Jung, G., Jeon, J., Choe, M. S., Kim, S.-W., Lee, I., Kim, M.-K., & Park, K.-G. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.3.211 · Cited by 28
“A reduction in albuminuria has been observed following inhibition with DPP-4, which is a biochemical hallmark of DKD in patients with type 2 diabetes [17,18].”
BackgroundDiabetes for Cardiologists: Practical Issues in Diagnosis and Management
Mancini, G. B. J., CHENG, A. Y. Y., Connelly, K. A., FITCHETT, D. H., Goldenberg, R., Goodman, S. G., Leiter, L. A., Lonn, E., Paty, B. W., Poirier, P., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.512 · Cited by 29
Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
Yandrapalli, S., & Aronow, W. S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.70 · Cited by 30
“The EXAmination of CV outcoMes with alogliptIN versus standard of carE (EXAMINE) trial randomized 5,380 T2DM patients with either an acute MI or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and CV drug therapy for…”
BackgroundMethodHernández, J. M. D. L. T., & Edelman, E. R. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.07.008 · Cited by 34
“There are examples of trials undergoing sample size re-estimation or changing the primary endpoint.(29,30)”
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Wang, X., Yang, L., Cheng, Y., Zheng, P., Hu, J., Huang, G., & Zhou, Z. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12873 · Cited by 29
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
Alfayez, O. M., Yami, M. S. A., Alshibani, M., Fallatah, S., Alkhushaym, N., Alsheikh, R., & Alkhatib, N. S. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.01.003 · Cited by 28
“A total of 14,752 patients with T2DM were enrolled.”
BackgroundInfluentialJong, C.-B., Chen, K., Hsieh, M., Su, F., Wu, C., Voon, W., Hsieh, C., Shyu, K., Chong, J., Lin, W., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.03.021 · Cited by 27
5 Conservative treatment for PAD – Risk factor management
Frank, U., Nikol, S., & Belch, J. J. F. (2019) · VASA · doi:10.1024/0301-1526/a000835 · Cited by 43
González, C. L., Atienza, E., Reyes-Umpierrez, D., Vellanki, P., Davis, G. M., Pasquel, F. J., Cardona, S., Fayfman, M., Peng, L., & Umpierrez, G. E. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0481 · Cited by 30
Schwartz, G. G., Nicholls, S. J., Toth, P. P., Sweeney, M., Halliday, C., Johansson, J. O., Wong, N. C. W., Kulikowski, E., Kalantar‐Zadeh, K., Ginsberg, H. N., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01311-9 · Cited by 30
“Medications that have shown favorable cardiovascular effects in stable patients have not been studied after ACS [metformin, sodium–glucose loop transporter-2 (SGLT2) inhibitors] and drugs in other classes that have been studied after ACS failed to show benefit [glucagon-like peptide-1 (GLP-1) receptor agonists, dipept…”
BackgroundAtrial Fibrillation and Diabetes Mellitus: Dangerous Liaisons or Innocent Bystanders?
Lorenzo-Almorós, A., Casado, J., Walther, L. A. Á.-S., Méndez‐Bailón, M., & Lorenzo, Ó. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082868 · Cited by 33
Leung, M., Leung, D. Y., & Wong, V. W. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116629352 · Cited by 29
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
“The cardiovascular outcome studies that have been completed with the DPP-4 inhibitors have achieved the principal non-inferiority end point but have not shown significant superiority on the 3point composite cardiovascular primary end point of cardiovascular death, myocardial infarction, or ischemic stroke for saxaglip…”
BackgroundAtkin, S. L., Katsiki, N., Banach, M., Mikhailidis, D. P., Pirro, M., & Sahebkar, A. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.016 · Cited by 27
Sharma, M., Beckley‐Hoelscher, N., Nazareth, I., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017260 · Cited by 28
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1171-0 · Cited by 32
Hirshberg, B., & Katz, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0663-9 · Cited by 28
Cardiovascular Effects of Incretin-Based Therapies
White, W. B., & Baker, W. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-050214-013431 · Cited by 26
Self-citationGiorda, C. B., Nada, E., Tartaglino, B., Marafetti, L., & Gnavi, R. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12297 · Cited by 30
Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
Trang, A., & Aguilar, D. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0371-7 · Cited by 28
Kim, K. J., Choi, J., Lee, J., Bae, J. H., An, J. H., Kim, H. Y., Yoo, H. J., Seo, J. A., Kim, N. H., Choi, K. M., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0835-z · Cited by 28
Kishimoto, S., Kinoshita, Y., Matsumoto, T., Maruhashi, T., Kajikawa, M., Matsui, S., Hashimoto, H., Takaeko, Y., Kihara, Y., Chayama, K., et al. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz065 · Cited by 29
Ferreira, J. P., Mehta, C. R., Sharma, A., Nissen, S. E., Rossignol, P., & Zannad, F. M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01616-8 · Cited by 27
Self-citationZhang, X., Wang, M., Wang, X., Zhu, Z., Zhang, W., Zhou, Z., Tang, W., & Li, Q. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.007 · Cited by 26
Deaminative (Carbonylative) Alkyl‐Heck‐type Reactions Enabled by Photocatalytic C−N Bond Activation
Jiang, X., Zhang, M., Xiong, W., Lu, L., & Xiao, W. (2018) · Angewandte Chemie · doi:10.1002/ange.201813689 · Cited by 26
Khera, R., Dhingra, L. S., Aminorroaya, A., Li, K., Zhou, J. J., Arshad, F., Blacketer, C., Bowring, M. G., Bu, F., Cook, M. B., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000651 · Cited by 32
Roshanov, P. S., & Dennis, B. B. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.014 · Cited by 26
“[4] White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.”
BackgroundMethodDoes glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?
Miki, T., Tobisawa, T., Sato, T., Tanno, M., Yano, T., Akasaka, H., Kuno, A., Ogasawara, M., Murase, H., Saitoh, S., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0125-8 · Cited by 30
Zheng, T., Liu, Y. H., Yang, L., Qin, S., & Liu, H. B. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.042 · Cited by 28
Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
John, M., Unnikrishnan, A., Kalra, S., & Nair, T. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.02.017 · Cited by 29
“With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA), Ertugliflozin CVOT).(10,11,22,23)”
BackgroundMethodDPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty
Filion, K. B., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dci15-0036 · Cited by 27
“In the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial, 5,380 patients with type 2 diabetes and a recent hospitalization for acute coronary syndrome were randomly assigned to alogliptin (Nesina in the U.S. and Vipidia in Europe) or placebo (7).”
InfluentialOn behalf of the PROTECT Study Investigators, Tanaka, A., Murohara, T., Taguchi, I., Eguchi, K., Suzuki, M., Kitakaze, M., Sato, Y., Ishizu, T., Higashi, Y., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0449-7 · Cited by 27
Terauchi, Y., Yamada, Y., Ishida, H., Ohsugi, M., Kitaoka, M., Satoh, J., Yabe, D., Shihara, N., & Seino, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12933 · Cited by 26
The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors
Avogaro, A., & Fadini, G. P. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13611 · Cited by 28
Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes
Libianto, R., Davis, T. M. E., & Ekinci, E. I. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50472 · Cited by 27
Acid-base and electrolyte disorders associated with the use of antidiabetic drugs
Filippatos, T. D., Tzavella, E., Rizos, C. V., Elisaf, M., & Liamis, G. L. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1361400 · Cited by 33
Heart Failure and Dipeptidyl Peptidase-4 Inhibitors
Krum, H., Skiba, M. A., Wu, S., & Hopper, I. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.90 · Cited by 27
Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?
Bhatt, D. L., & Cavender, M. A. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2014.05.005 · Cited by 26
Report from the 5th cardiovascular outcome trial (CVOT) summit
Schnell, O., Standl, E., Cos, X., Heerspink, H. J. L., Itzhak, B., Lalic, N. M., Nauck, M. A., & Ceriello, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01022-7 · Cited by 28
Birnbaum, G. D., Birnbaum, I., Ye, Y., & Birnbaum, Y. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6615-4 · Cited by 27
“However, two clinical trials failed to show reduction of cardiovascular events with long term treatment with DPP-IV inhibitors [46, 47].”
BackgroundPotential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure
Salles, T. A., dos SANTOS, L., Baraúna, V. G., & Girardi, A. C. C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024226 · Cited by 28
“The EXAMINE trial was a multicenter, randomized, double-blind trial [145].”
MethodClarke, S. J., McCormick, L. M., & Dutka, D. P. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-12 · Cited by 29
“for type-2 diabetes [96,97].”
Htoo, P. T., Buse, J. B., Gokhale, M., Marquis, M. A., Pate, V., & Stürmer, T. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2068-3 · Cited by 25
Chang, C., Chang, Y., Lin, J., Caffrey, J. L., Wu, L., Lai, M., & Chuang, L. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.125 · Cited by 25
Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease
Yang, G., Li, Y.-Z., Cui, L., Jiang, H., Li, X., Jin, C., Jin, D., Zhao, G., Jin, J., Sun, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163027 · Cited by 27
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
Zonszein, J., & Groop, P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0208-5 · Cited by 32
Diabetes and Hypertension: Clinical Update
Khangura, D., Kurukulasuriya, L. R., Whaley‐Connell, A. T., & Sowers, J. R. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy025 · Cited by 27
Shah, D., Risebrough, N. A., Perdrizet, J. E., Iyer, N. N., Gamble, C. L., & Dang‐Tan, T. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s180067 · Cited by 27
Nauck, M. A., McGuire, D. K., Pieper, K. S., Lokhnygina, Y. V., Strandberg, T. E., Riefflin, A., Delibaşı, T., Peterson, E. D., White, H. D., Scott, R. S., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0921-2 · Cited by 25
Association between Variability of Metabolic Risk Factors and Cardiometabolic Outcomes
Park, M., & Choi, K. M. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0316 · Cited by 32
“blunted glucose fluctuation [42-44], other studies reported that DPP4 inhibitors were unsuccessful in reducing ASCVD risk [45,46].”
ResultHasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 27
Brønden, A., Christensen, M., Glintborg, D., Snorgaard, O., Kofoed‐Enevoldsen, A., Madsen, G. K., Toft, K., Kristensen, J. K., Højlund, K., Hansen, T. K., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15157 · Cited by 37
Nozue, T., Yamada, M., Tsunoda, T., Katoh, H., Ito, S., Iwaki, T., & Michishita, I. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0734-5 · Cited by 25
Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm
DeJongh, B. M., Birkeland, K. T., & Brenner, M. J. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0115-6 · Cited by 28
“11) [34].”
Incretin‐based medications for type 2 diabetes: an overview of reviews
Gamble, J., Clarke, A. M. F., Myers, K. J., Agnew, M. D., Hatch, K., Snow, M., & Davis, E. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12465 · Cited by 27
“Indeed, the results of many included reviews appear to overestimate the cardiovascular benefits of DDP-4 inhibitors when compared with the neutral findings of two recent randomized controlled trials, which evaluated the risk of cardiovascular outcomes among two different DPP-4 inhibitors, saxagliptin (SAVOR-TIMI 53) a…”
ResultYang, T., Liaw, Y., Huang, J., Chang, H., Chang, K.-W., & Ueng, K. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0817-x · Cited by 25
“Another EXAMINE trial demonstrated that the therapy of Alogliptin resulted in rates of macrovascular end points that were similar to rates with placebo in patients with diabetes who had recent acute coronary syndrome [18].”
ResultBonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 26
“In the EXAMINE study [121] more than 5000”
BackgroundSitagliptin After Ischemic Stroke in Type 2 Diabetic Patients
Chen, D., Wang, S.-H., Mao, C., Tsai, M., Lin, Y., Su, F.-C., Chou, C., Wen, M., Wang, C., Hsieh, C., et al. (2015) · Medicine · doi:10.1097/md.0000000000001128 · Cited by 24
“On the contrary, two recently published studies on saxagliptin and alogliptin did not find any beneficial effect on cardiovascular outcomes or stroke.(12,13) As a result, there is ongoing debate about the cardiovascular benefits and potential risks of DPP-4 inhibitors.”
BackgroundResult
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.